Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience.
Elsharkawy A, El-Raziky M, El-Akel W, El-Saeed K, Eletreby R, Hassany M, El-Sayed MH, Kabil K, Ismail SA, El-Serafy M, Abdelaziz AO, Shaker MK, Yosry A, Doss W, El-Shazly Y, Esmat G, Waked I. Elsharkawy A, et al. J Hepatol. 2018 Apr;68(4):691-698. doi: 10.1016/j.jhep.2017.11.034. Epub 2017 Dec 6. J Hepatol. 2018. PMID: 29223371
Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.
El Kassas M, Omran D, Elsaeed K, Alboraie M, Elakel W, El Tahan A, Abd El Latif Y, Nabeel MM, Korany M, Ezzat S, El-Serafy M, ElShazly Y, Doss W, Esmat G. El Kassas M, et al. Among authors: elsaeed k. J Interferon Cytokine Res. 2018 Feb;38(2):81-85. doi: 10.1089/jir.2017.0121. Epub 2018 Jan 22. J Interferon Cytokine Res. 2018. PMID: 29356573
An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens.
El Kassas M, Alboraie M, Omran D, Salaheldin M, Wifi MN, ElBadry M, El Tahan A, Ezzat S, Moaz E, Farid AM, Omar H, Abouelkhair M, Afify S, Elsaeed K, Shazly Y, Doss W, Esmat G. El Kassas M, et al. Among authors: elsaeed k. Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1265-1272. doi: 10.1080/17474124.2018.1476137. Epub 2018 May 24. Expert Rev Gastroenterol Hepatol. 2018. PMID: 29757684
High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
El Kassas M, Alboraie M, Omar H, El Latif YA, Algaber MA, El Tahan A, El Halwagy H, Afify S, Elserafy M, Elsaeed K, Doss W. El Kassas M, et al. Among authors: elsaeed k. J Med Virol. 2022 Feb;94(2):667-674. doi: 10.1002/jmv.25478. Epub 2019 Apr 15. J Med Virol. 2022. PMID: 30950069
High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study.
Darweesh SK, Elsaeed K, Omar H, El Raziky M, Elakel W, Elserafy M, Ismail SA, Gomaa AA, Mehrez M, El Kassas M, Abdullah M, Shaker MK, Esmat G, El Shazly Y, Doss W, Waked I. Darweesh SK, et al. Among authors: elsaeed k. Expert Rev Gastroenterol Hepatol. 2019 Sep;13(9):907-914. doi: 10.1080/17474124.2019.1629287. Epub 2019 Jun 23. Expert Rev Gastroenterol Hepatol. 2019. PMID: 31173527
Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.
El-Sayed M, Elserafy M, El Raziky M, Elakel W, Saad Y, Fayad T, Korany M, Mehrez M, Salama R, Mahrous M, Zaki A, Hassany M, Ammar I, Elsaeed K, Elshazly Y, Doss W. El-Sayed M, et al. Among authors: elsaeed k. Arab J Gastroenterol. 2023 Feb;24(1):29-33. doi: 10.1016/j.ajg.2022.10.001. Epub 2023 Feb 20. Arab J Gastroenterol. 2023. PMID: 36813580
21 results